title: Combining Ipilimumab and Bevacizumab in Glioblastoma is Really Safe and Effective?
authors.affiliation: IstitutoToscanoTumori, Firenze, Italy; Unit of Radiation Oncology, University Hospital of Siena, Siena, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Tini
authors.affiliation: IstitutoToscanoTumori, Firenze, Italy; Unit of Radiation Oncology, University Hospital of Siena, Siena, Italy; Radiation Oncology, Department of Medicine, Surgery and Neurological Sciences, University of Siena, Siena, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Pirtoli
mesh_terms: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001932:Brain Neoplasms; D005909:Glioblastoma; D006801:Humans; D000074324:Ipilimumab; D009364:Neoplasm Recurrence, Local; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000074324:Ipilimumab; D000068258:Bevacizumab